<DOC>
	<DOCNO>NCT01466114</DOCNO>
	<brief_summary>Approximately 50 % people diagnosed Multiple Sclerosis ( MS ) develop problem cognition . Currently , FDA-approved treatment target cognitive function Multiple Sclerosis . This trial ascertain whether treatment estrogen pill , use combination standard MS anti-inflammatory drug , improve cognitive testing compare treatment placebo pill combination standard anti-inflammatory drug woman MS .</brief_summary>
	<brief_title>Estriol Treatment Multiple Sclerosis ( MS ) : Effect Cognition</brief_title>
	<detailed_description>Approximately 50 % people diagnosed Multiple Sclerosis ( MS ) develop problem cognition . Currently , FDA-approved treatment cognitive function Multiple Sclerosis . Multiple sclerosis relapse know significantly decrease approximately 80 % late pregnancy . This disease improvement may due estriol , estrogen unique pregnancy . Estriol blood level go undetectable level prior pregnancy , increase pregnancy reach high level late pregnancy . Further , estrogen treatment show favorable effect cognition animal model neurological disease . This proposal establish whether oral treatment estriol , induces improvement cognitive functioning subject multiple sclerosis use combination major FDA-approved standard treatment MS , ( Betaseron® ( Extavia® ) , Rebif® , Avonex® , Copaxone® , Gilenya® , Aubagio® , Tecfidera® ) . The combination standard MS treatment plus estriol pill ( 8 mg per day ) compare standard MS treatment plus placebo double-blinded fashion . The duration treatment one year primary outcome measure cognitive testing process speed ability . Secondary outcome improvement cognitive test , brain MRIs , cognitive evoke potential , well relapse rate disability measure ( EDSS , 25 foot walk , 9 hole peg test , low contrast visual acuity , MS Quality Life , Modified Fatigue Impact Scale , Beck Depression Inventory , Level Activity use accelerometry ) . Safety measure ( blood test gynecologic evaluation ) also follow . The overall goal study development oral treatment , estriol , improve cognitive function MS .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<criteria>Diagnosis clinically definite MacDonald criterion relapsingremitting multiple sclerosis , secondaryprogressive multiple sclerosis primaryprogressive multiple sclerosis . No relapse within 30 day day trial enrollment ( month 0 visit ) . If steroid give relapse , month 0 visit must 30 day last steroid dose . Females age 18 50 , inclusive . Expanded Disability Status Score ( EDSS ) = 0.0 6.0 . Screening PASAT ( 3second ) score 2550 , inclusive . Must mentally competent enough comply study guideline give informed consent . Must willing able travel study center frequency protocol total period 12 month . Patients must treatment stable dose one follow agent minimum 3 month duration prior month 0 visit : Copaxone® , Betaseron® ( Extavia® ) , Rebif® , Avonex® , Gilenya® , Aubagio® , Tecfidera® . The time spent screen period may serve part 3month period . Patients currently treat ACTH , corticosteroid , intravenous immunoglobulin ( IVIG ) , plasma exchange , Lipitor® minocycline may include . If patient plan start treatment Copaxone® interferon [ Betaseron® ( Extavia® ) , Rebif® , Avonex® ] oral agent [ Gilenya® , Aubagio® Tecfidera® ] must least 3 month prior month 0 ( ) . Males Subjects oral contraceptive ( OCP ) , hormone replacement therapy ( HRT ) sex hormone screen 12month study period ( Mirena® IUD permit ) . Females pregnant plan become pregnant 12 month enrollment , wish become pregnant within 3 month follow completion study , within 6 month post partum day first enrollment visit ( month 0 ) . Females plan breastfeed first enrollment visit ( month 0 ) . Fertile sexually active woman unwilling practice reliable barrier method contraception oral contraceptive ( i.e . condom , diaphragm , IUDs Note : Hormonal IUD [ Mirena® ] permit ) . Patients surgical ovariectomy hormone replacement 1 year . Menopause hormone replacement 3 year prior first enrollment visit . Patients smoke time screen 12 month study period . Patients serious pulmonary , renal , gastrointestinal , hepatic , immunologic , infectious , neoplastic , major psychiatric disease ( major depression , schizophrenia ) , endocrine disease ( include major diabetes , thyroid disease ) , gynecologic disease , include limited : Thrombophlebitis thromboembolic disorder , past history deep vein thrombophlebitis thromboembolic disorder , cerebral vascular coronary artery disease , migraine focal aura , know suspect carcinoma breast , carcinoma endometrium know suspected estrogendependent neoplasia , undiagnosed abnormal genital bleeding , polycystic ovary disease , amenorrhea unknown etiology , cholestatic jaundice pregnancy jaundice prior birth control pill use , acute chronic hepatocellular disease abnormal liver function , hepatic adenoma carcinoma , know suspected pregnancy , know hypersensitivity birth control pill Copaxone Betaseron use . B12 level &lt; 200 . Drug abuse within past five year . Conditions would interfere assess neurologic function deform arthritis major amputation . Have time treat total lymphoid irradiation , monoclonal antibody , T cell vaccination , cladribine , bone marrow transplantation , azathioprine , cyclophosphamide , methotrexate , mitoxantrone , cyclosporine . Have treat natalizumab ( Tysabri® ) 6 month prior screen . Positive titer HIV past . Previous serious adverse effect estrogen treatment . Patients participate previous multicenter estriol trial RRMS ( `` A Combination Trial Copaxone plus Estriol RRMS '' ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>relapse remit multiple sclerosis</keyword>
	<keyword>RRMS</keyword>
	<keyword>secondary progressive multiple sclerosis</keyword>
	<keyword>SPMS</keyword>
	<keyword>primary progressive multiple sclerosis</keyword>
	<keyword>estrogen</keyword>
	<keyword>estriol</keyword>
</DOC>